Cost-Effectiveness Comparison of Salmeterol/Fluticasone Propionate versus Montelukast in the Treatment of Adults with Persistent Asthma

被引：0
作者：
Ketan Sheth
Rohit Borker
Amanda Emmett
Kathleen Rickard
Paul Dorinsky
机构：
[1] Allergy/Asthma Section,
[2] Arnett Clinic,undefined
[3] GlaxoSmithKline Inc.,undefined
来源：
PharmacoEconomics | 2002年 / 20卷
关键词：
Fluticasone Propionate; Salmeterol; Montelukast; Persistent Asthma; Propionate Group;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To compare the relative cost effectiveness of salmeterol (50μg)/ fluticasone propionate (100μg) with that of oral montelukast (10mg) as initial maintenance therapy in patients with persistent asthma uncontrolled on short-acting β2-agonist therapy alone.
引用
收藏
页码：909 / 918
页数：9
相关论文
共 43 条
[1]  
Weiss K(1998)Forecasted state-specific estimates of self-reported prevalence in the United States, 1998 Morb Mortal Wkly Rep 47 1022-5
[2]  
Sullivan S(2001)The health economics of asthma and rhinitis: assessing the economic impact J Allergy Clin Immunol 107 3-8
[3]  
Lundback B(2000)Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma Respir Med 94 724-32
[4]  
Jenkins C(2000)Risk factors and costs associated with an asthma attack Thorax 55 19-24
[5]  
Price M(2001)Psychopathology in patients with severe asthma is associated with increased health care utilization Am J Respir Crit Care Med 163 1093-6
[6]  
Hoskins G(1998)Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma Arch Intern Med 158 1213-20
[7]  
McCowan C(2001)Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short acting β2 agonists alone Am J Respir Crit Care Med 164 759-63
[8]  
Neville R(1999)The cost of asthma in the emergency department and hospital Am J Respir Crit Care Med 160 211-5
[9]  
Brinke A(2000)Charge what you will...Reimbursements are shrinking Med Econ 75 128-38
[10]  
Ouwerkerk M(1999)What is mean by intention to treat analysis: survey of published randomized controlled trials BMJ 319 670-4
12345